…TIMESLOT: Tuesday 14 May – 16:00 – 17:00 CEST
…THEME: N-of-1 to many personalized therapies
…PRESENTERS: Terry Pirovolakis, Founder of CureSPG50 and Elpida Therapeutics
Terry Pirovolakis, co-founder of CureSPG50, confronted his child’s SPG50 diagnosis in 2019. Through successful fundraising, he led ground-breaking research, treating three children within three years. Pirovolakis established Elpida Therapeutics, a corporation with a non-profit approach, focusing on gene therapies for ultra-rare conditions. Collaborating with industry leaders, Elpida targets SPG50, CMT4J, and plans to address three more diseases in 2024, utilizing profits to sustain programs. Pirovolakis extends his impact by supporting foundations, providing Gene Therapy 101 classes, and engaging in collaborations, all centered on the goal of saving as many children as possible.